BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is expected to post earnings of $0.46 per share


Wall Street analysts expect BioMarin Pharmaceutical Inc. (NASDAQ: BMRNGet a rating) to post earnings per share (EPS) of $0.46 for the current quarter, according to Zacks Investment Research. Ten analysts have released earnings estimates for BioMarin Pharmaceutical, with estimates ranging from $0.07 to $0.65. BioMarin Pharmaceutical reported earnings per share of $0.53 in the same quarter last year, indicating a negative 13.2% year-over-year growth rate. The company is due to release its next results on Monday, January 1.

According to Zacks, analysts expect BioMarin Pharmaceutical to report annual earnings of $1.91 per share for the current year, with EPS estimates ranging from $1.32 to $2.10. For the next fiscal year, analysts expect the company to post earnings of $3.86 per share, with EPS estimates ranging from $2.69 to $4.52. Zacks earnings per share calculations are an average based on a survey of analysts who follow BioMarin Pharmaceutical.

BioMarin Pharmaceutical (NASDAQ: BMRNGet a rating) last reported results on Wednesday, April 27. The biotech company reported earnings per share of $0.63 for the quarter, beating Thomson Reuters consensus estimate of $0.15 by $0.48. BioMarin Pharmaceutical achieved a net margin of 2.09% and a return on equity of 1.37%. In the same period a year earlier, the company posted earnings per share of $0.29.

BMRN has been the subject of several reports by research analysts. StockNews.com launched coverage on BioMarin Pharmaceutical in a research note on Thursday, March 31. They have placed a “holding” rating on the stock. Wedbush lowered its price target on BioMarin Pharmaceutical from $155.00 to $147.00 in a Thursday, April 28 research report. Truist Financial raised its price target on BioMarin Pharmaceutical from $125.00 to $135.00 in a Monday, January 10 research report. Morgan Stanley moved shares of BioMarin Pharmaceutical from an “equal weight” rating to an “overweight” rating and raised its price target for the company from $96.00 to $113.00 in a report from the Monday, April 25. Finally, Piper Sandler raised her price target on shares of BioMarin Pharmaceutical from $121.00 to $125.00 and gave the stock an “overweight” rating in a Thursday, February 24 report. Four investment analysts gave the stock a hold rating and eleven gave the company a buy rating. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $112.79.

In other news from BioMarin Pharmaceutical, CEO Jean-Jacques Bienaime sold 20,000 shares of the company in a transaction dated Thursday, April 28. The shares were sold at an average price of $83.79, for a total transaction of $1,675,800.00. Following the completion of the sale, the CEO now directly owns 334,983 shares of the company, valued at $28,068,225.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available via this link. Also, director Denis Slamon sold 6,396 shares of the company in a transaction that took place on Monday, February 28. The shares were sold at an average price of $78.33, for a total transaction of $500,998.68. Disclosure of this sale can be found here. In the past 90 days, insiders have sold 90,702 shares of the company worth $7,395,992. 1.75% of the shares are currently held by insiders of the company.

A number of institutional investors have recently increased or reduced their stake in the company. Ancora Advisors LLC increased its stake in shares of BioMarin Pharmaceutical by 466.7% in the third quarter. Ancora Advisors LLC now owns 425 shares of the biotech company worth $33,000 after acquiring 350 additional shares in the last quarter. Spire Wealth Management increased its stake in shares of BioMarin Pharmaceutical by 59.7% in the fourth quarter. Spire Wealth Management now owns 377 shares of the biotech company valued at $33,000 after purchasing an additional 141 shares during the period. Liberty Wealth Management LLC increased its position in BioMarin Pharmaceutical by 181.7% during the third quarter. Liberty Wealth Management LLC now owns 431 shares of the biotech company worth $34,000 after buying 278 more shares last quarter. CWM LLC increased its stake in BioMarin Pharmaceutical by 435.2% during the first quarter. CWM LLC now owns 487 shares of the biotech company valued at $38,000 after acquiring 396 additional shares during the period. Finally, Desjardins International Asset Management Inc. acquired a new position in BioMarin Pharmaceutical in Q4 worth approximately $53,000. 95.45% of the shares are held by hedge funds and other institutional investors.

Shares of NASDAQ BMRN opened at $83.31 on Tuesday. The stock has a market capitalization of $15.40 billion, a P/E ratio of 462.83, a PEG ratio of 1.81 and a beta of 0.49. The stock’s 50-day moving average price is $79.97 and its two-hundred-day moving average price is $83.47. The company has a quick ratio of 2.77, a current ratio of 4.21 and a leverage ratio of 0.25. BioMarin Pharmaceutical has a 52 week low of $71.59 and a 52 week high of $94.20.

BioMarin Pharmaceutical Company Profile (Get a rating)

BioMarin Pharmaceutical Inc develops and markets therapies for people with rare diseases and serious, life-threatening medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Featured Articles

Get a Free Copy of Zacks’ Research Report on BioMarin Pharmaceutical (BMRN)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com



Get news and reviews for BioMarin Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com’s free daily email newsletter.